Contineum Therapeutics Current Cash

Contineum Therapeutics's current cash stands at $15M as of June 2026. That compares with $21M in the prior-year period — down 29.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Contineum Therapeutics reported $15M in current cash versus $21M a year earlier — a 29.2% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $21M in the prior-year period — down 29.2% year over year. Sustained growth in current cash can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Contineum Therapeutics's current cash evolved across reporting periods, while the comparison chart places CTNM next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.